Log in to search using one of your social media accounts:

 

Brooks Memorial to close dialysis unit, transition patients to new DaVita clinic
Three years after first proposing to close its dialysis service, Brooks Memorial Hospital is now moving forward with that plan just as a privately-owned national dialysis company prepares to open a clinic in Dunkirk. The hospital filed plans with the state Department of Health to discontinue outpatient dialysis services in the hospital and discontinue home peritoneal dialysis training and support. The program currently serves 33 patients. The decision also affects seven nurses who run the program.  The… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - November 6, 2017 Category: Health Management Authors: Tracey Drury Source Type: news

Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts - Petrous J, Furmaga K.
A 59-year-old woman on daily peritoneal dialysis for end-stage renal failure received care at an outpatient psychiatric clinic for her diagnoses that include major depressive disorder, generalised anxiety disorder and insomnia disorder. Although there was ... (Source: SafetyLit)
Source: SafetyLit - October 30, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Initiating Peritoneal Dialysis After Catheter Insertion Initiating Peritoneal Dialysis After Catheter Insertion
Dr Desai discusses the uncertainty that remains about commencement of dialysis after catheter insertion.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2017 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

Kenya: Medics Urge State to Expand NHIF Cover for Kidney Treatment
[Nation] Medics want the National Hospital Insurance Fund (NHIF) cover to be expanded to cater for both peritoneal dialysis as well as post-transplant care of kidney patients. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 27, 2017 Category: African Health Source Type: news

7 medtech stories we missed this week: Sept. 15, 2017
[Image from unsplash.com]From Acera Surgical and Telos Medical’s partnership to Xtant Medical’s 510(k) clearance, here are seven medtech stories we missed this week but thought were still worth a mention. 1. Acera Surgical partners with Telos Medical for Restrata wound matrix trial Telos Partners announced in a Sept. 14 press release that Acera Surgical has chosen Telos to lead its Restrata wound matrix study. The study will surgery the clinical outcomes of Restrata treatments for diabetic foot ulcers and test for effectiveness and safety. Restrata is a fully synthetic wound matrix that is FDA-cleared for ...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Business/Financial News Clinical Trials Dental Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance Surgical Acera Surgical Contego Medical Fresenius MedTech OBP Medical Pinnacle Sciences Plusoptix Telos Source Type: news

Baxter inks tech transfer deal for surgical devices out of Tel Aviv University
Baxter‘s (NYSE:BAX) said today it inked a licensing agreement with Tel Aviv University’s Ramot business engagement center through which the company aims to bring early stage research technologies in development at the university to the market. As part of the agreement, Baxter said it will gain an exclusive license for the TAU Technology Innovation Momentum Fund tech in 1 license agreement and TAU and Tel Aviv Sourasky Medical Center tech in a 2nd. “Baxter is committed to finding creative pathways to bring innovative solutions to the operating room. By working with leading experts at TAU and TASMC, we...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Baxter Source Type: news

Local amplifiers of IL-4R{alpha}-mediated macrophage activation promote repair in lung and liver
The type 2 immune response controls helminth infection and maintains tissue homeostasis but can lead to allergy and fibrosis if not adequately regulated. We have discovered local tissue-specific amplifiers of type 2–mediated macrophage activation. In the lung, surfactant protein A (SP-A) enhanced interleukin-4 (IL-4)–dependent macrophage proliferation and activation, accelerating parasite clearance and reducing pulmonary injury after infection with a lung-migrating helminth. In the peritoneal cavity and liver, C1q enhancement of type 2 macrophage activation was required for liver repair after bacterial infectio...
Source: ScienceNOW - June 8, 2017 Category: Science Authors: Minutti, C. M., Jackson-Jones, L. H., Garcia-Fojeda, B., Knipper, J. A., Sutherland, T. E., Logan, N., Rinqvist, E., Guillamat-Prats, R., Ferenbach, D. A., Artigas, A., Stamme, C., Chroneos, Z. C., Zaiss, D. M., Casals, C., Allen, J. E. Tags: Immunology reports Source Type: news

Baxter touts Sharesource in-home peritoneal dialysis patient monitoring study data
Baxter (NYSE:BAX) today released data from multiple studies of its Sharesource remote patient monitoring technology used for peritoneal dialysis patient care. Data from the study was presented at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association meeting this week. Sharesource is a 2-way cloud-based technology offered with the company’s Homechoice Claria automated PD system to allow providers to connect with patients using the device and verify patient adherence, the company said. Data from the 1st study study, which included 399 APD patients using remote patient...
Source: Mass Device - June 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Patient Monitoring Baxter Source Type: news

Baxter inks R & D deal with Mayo Clinic, initial focus on kidney disease
Baxter (NYSE:BAX) said today that it inked a research & development collaborative deal with the Mayo Clinic to develop new technologies and therapies designed to improve patient therapeutic care. The pair will initially focus on kidney disease, with additional projects planned in other areas where breakthrough treatment options can be introduced and innovation can improve access to high-quality care. “We are excited about combining Mayo’s clinical and research expertise with Baxter’s ability to apply and scale innovation. We are confident that this collaboration will help accelerate discoveries, ...
Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Baxter Source Type: news

DaVita buys Delafield dialysis clinic operator
DaVita Kidney Care said Monday that it has purchased a Delafield operator of dialysis clinics less than one week after reporting a tough quarter and two other acquisitions. DaVita Kidney Care, a division of Denver-based DaVita Inc. (NYSE: DVA), acquired Purity Dialysis, which has 10 centers in the Milwaukee area. Purity Dialysis clinics also provide outpatient hemodialysis and in-home peritoneal dialysis training. Terms of the deal were not disclosed. DaVita operat es about a dozen clinics in Milwaukee… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 9, 2017 Category: Pharmaceuticals Authors: Caitlin Hendee Source Type: news

DaVita scoops up Wisconsin operator of dialysis clinics
DaVita Kidney Care announced Monday that it has scooped up a Wisconsin operator of 10 dialysis clinics less than one week after reporting a tough quarter and two other acquisitions. DaVita Kidney Care, a division of Denver-based DaVita Inc. (NYSE: DVA), acquired Purity Dialysis, which has 10 centeres in the greater Milwaukee area. Purity Dialysis clinics also provide out-patient hemodialysis and in-home peritoneal dialysis training. Terms of the deal were not disclosed. "We look forward to providing… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 8, 2017 Category: American Health Authors: Caitlin Hendee Source Type: news

Baxter looks to combination device pathway for home peritoneal dialysis machine
Baxter (NYSE:BAX) said today that after communicating with the FDA, it will pursue a regulatory pathway as a combination product for its new home peritoneal dialysis solution system. The system is desigend to produce sterile PD solutions using a small water filtration device designed to be placed in a patient’s home and integrated into its AMIA automated peritoneal dialsysis system, the Deerfield, Ill.-based company said. “The FDA’s guidance is a pivotal milestone in advancing our new system forward for use by renal patients in an expedient manner. These technology advancements have the potential to ...
Source: Mass Device - May 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Food & Drug Administration (FDA) Regulatory/Compliance Baxter Source Type: news

Peritoneal Dialysis Safe for Post-Op Fluid Overload in Infants with CHD
(MedPage Today) -- Diuretics linked to higher risk of prolonged ventilation (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 21, 2017 Category: Surgery Source Type: news

Myths in Peritoneal Dialysis Myths in Peritoneal Dialysis
Common misperceptions about peritoneal dialysis may influence the practices of this therapy. Find out what they are.Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2017 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

New method makes peritoneal dialysis more tolerable
The addition of a new type of fluid for use in peritoneal dialysis makes it easier to tolerate and protects the cells in the abdominal cavity. This could make the peritoneum more resilient to harmful effects, report investigators. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 22, 2016 Category: Science Source Type: news

Baxter touts data on home peritoneal dialysis
Baxter (NYSE:BAX) today released data on its Sharesource remote patient monitoring and home-use Amia automated peritonial dialysis systems, touting its ability to improve early detection of adverse issue issues and faster treatment. Data on the platforms was presented at the American Society of Nephrology’s annual Kidney Week meeting last week in Chicago. Data from a case study of Baxter’s Sharesource indicated that the system was able to identify a displaced catheter through an early alert and diagnosis, which was surgically repositioned, the company said. A simulation study of 12 APD patient profiles ind...
Source: Mass Device - November 21, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Clinical Trials Patient Monitoring Baxter Source Type: news

Extraneal (Icodextrin Peritoneal Dialysis Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Dianeal Low Calcium (Low Calcium Peritoneal Dialysis Solutions) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 2, 2016 Category: Drugs & Pharmacology Source Type: news

Dianeal PD-1 (Peritoneal Dialysis Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 2, 2016 Category: Drugs & Pharmacology Source Type: news

Dianeal PD-2 (Peritoneal Dialysis Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 2, 2016 Category: Drugs & Pharmacology Source Type: news

Baxter, Satellite Healthcare ink dialysis deal
Baxter (NYSE:BAX) and Satellite Healthcare said today that they inked a deal to bring Baxter’s dialysis products into Satellite’s 80-site renal care network. Satellite, a non-profit group, is the 6th-largest dialysis and kidney disease treatment provider in the U.S. The 4-year deal will see Satellite deploy Baxter’s Amia automated peritoneal dialysis system and Revaclear dialyzer for high-flux hemodialysis. Baxter won 510(k) clearance from the FDA in October 2015 for the Amia system. The financial details of the agreement were not disclosed. “Baxter and Satellite Healthcare ...
Source: Mass Device - August 25, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Dialysis Wall Street Beat Baxter International Satellite Healthcare Source Type: news

Two classes of medications linked to similar results in peritoneal dialysis patients
A new study examined two classes of medications commonly prescribed to prevent cardiovascular events in dialysis patients and found no significant difference in outcomes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 8, 2016 Category: Science Source Type: news

NxStage Medical Details New Features, Hints at Peritoneal Dialysis System
(Source: MDDI)
Source: MDDI - August 8, 2016 Category: Medical Equipment Authors: mthibault Tags: Development Medical Device Business Source Type: news

Two classes of medications linked to similar results in peritoneal dialysis patients
(LA BioMed) A new study examined two classes of medications commonly prescribed to prevent cardiovascular events in dialysis patients and found no significant difference in outcomes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 8, 2016 Category: Global & Universal Source Type: news

Baxter touts study indicating cost savings with Revaclear dialyzer
This study suggests that clinicians may be able to reduce patient exposure to ESAs without sacrificing hemoglobin levels,” study author Dr. Maggie Gellens said in a press release. Decreasing ESA use by an average dose of 275 units would mean potential savings of $4.39 per hemodialysis session, according to the report, which comes out to $660 savings per patient per year at 3 dialysis sessions a week. ”Reducing the cost of one hemodialysis session can be significant considering that more than 60 million hemodialysis sessions are delivered in the U.S. annually,” Baxter global HEOR senior director Suzanne La...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Clinical Trials Baxter International Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 29, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. ‘Donnie Brasco’ brother sues Zimmer A former sales rep for Zimmer Biomet – who is the brother of the FBI agent on whom the movie “Donnie Brasco” is based – yesterday filed a $15 million lawsu...
Source: Mass Device - June 29, 2016 Category: Medical Equipment Authors: Melissa Annand Tags: News Well Plus 5 Source Type: news

Baxter wins Health Canada nod for Amia peritoneal dialysis system
Baxter (NYSE:BAX) said today that it won a nod north of the border for its Amia automated peritoneal dialysis system. The Health Canada approval makes Amia the 1st automated peritoneal dialysis device cleared in the U.S. and Canada that includes voice guidance, touchscreen control and 2-way telemedicine features, Deerfield Park, Ill.-based Baxter said. “As a leader in home dialysis, Baxter is committed to understanding patients’ and clinicians’ needs, so we can provide innovative therapy options that are designed to support access to care where and when it’s needed,” Baxter Cana...
Source: Mass Device - June 29, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Dialysis Regulatory/Compliance Baxter International Health Canada Source Type: news

Baxter touts remote monitoring study for Amia dialysis device
Baxter (NYSE:BAX) today released the results from a study of its AMIA automated peritoneal dialysis system, touting the value of remote monitoring technology for chronic health conditions for improving access to care, decreasing hospitalization and reducing treatment costs. Results from the study were published in the academic journal Plos One this month, the company said. ”Increasing healthcare costs and a growing number of chronically ill patients are driving the need for more affordable and innovative options, like remote monitoring that may support better delivery of home healthcare. Baxter conducted this st...
Source: Mass Device - June 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Clinical Trials Patient Monitoring Baxter International Source Type: news

New treatment approaches to improve peritoneal dialysis
One of the main functions of the kidneys is to filter metabolic products out of the blood. If the kidneys are no longer able to do this, the blood has to be artificially purified and drained of excess fluid. This is the purpose of dialysis. Now researchers are seeking new, better therapeutic approaches for those patients on dialysis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 24, 2016 Category: Science Source Type: news

Blood pressure medications reduce stroke, heart attack in peritoneal dialysis patients
Two classes of blood pressure medications are associated with a 16 percent lower risk of cardiovascular events in patients who are undergoing peritoneal dialysis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 14, 2016 Category: Science Source Type: news

NxStage Medical jumps on Baxter’s exit from the home hemodialysis market
Share prices for NxStage Medical (NSDQ:NXTM) jumped this week after Baxter (NYSE:BAX) CEO Joe Almeida said the company is pulling the plug on its Vivia home hemodialysis device. Almeida, speaking at the Goldman Sachs investor conference June 7, said he evaluated the home dialysis market after he took over the corner office in October 2015. “That is a very high hurdle, technologically speaking, because it’s a very difficult thing to achieve on an assisted basis,” Almeida said. In evaluating the market, Almeida said he looked at 2 companies in the home dialysis arena: San Jose, Calif.-based Outset...
Source: Mass Device - June 9, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Dialysis Wall Street Beat Baxter International NxStage Medical Inc. Source Type: news

Sunrise Labs welcomes Doug Browne and Dave Hibbard to the team
Sunrise Labs, an ISO-13485 certified medical device product development firm in Auburn, NH, is proud to announce the addition of two engineers in leadership roles; Doug Browne, Director of Mechanical Engineering & Design Transfer and Dave Hibbard, Program Manager. Doug Browne has over 25 years of experience in medical device, bio-technology and mechanical system product development focusing on mechanical design, plastics, and design transfer. As technical lead for development and launch of over ten major new products, Doug is recognized as an innovative and award winning product designer. He has particular expertise in...
Source: Mass Device - June 6, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Sunrise Labs Source Type: news

Flu Vaccine and Morbidity and Mortality in Dialysis PatientsFlu Vaccine and Morbidity and Mortality in Dialysis Patients
End-stage renal disease patients on peritoneal dialysis who received a flu vaccine realized a lower risk of morbidities and mortality than those who were non-vaccinated. Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 24, 2016 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Baxter launches trial for Vivia home hemodialysis system
Baxter (NYSE:BAX) said today that it’s launching a clinical trial of the Vivia home hemodialysis device it’s co-developing with famed inventor Dean Kamen’s DEKA Research & Development Corp. The Vivia system is designed to provide shorter but more frequent dialysis rounds than conventional dialysis. The device has already won CE Mark approval in the European Union for use with Baxter’s Sharesource remote monitoring system, the company said. Deerfield, Ill.-based Baxter said the 20-patient efficacystudy is designed to evaluate the Vivia system for frequent, extended nocturnal d...
Source: Mass Device - March 15, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Dialysis Baxter International Renal Source Type: news

NxStage touts home hemodialysis studies
NxStage Medical (NSDQ:NXTM) today touted data from studies of its Nx2me connected health technology and home hemodialysis systems, which the company plans to present at the 2016 Annual Dialysis Conference in Seattle later this month. In a study of 328 patients treated with the company’s HHD using its Nx2me platform, NxStage reported a 44% reduction in controllable dropout when compared against patients not treated with the telehealth system. The Nx2me Connected Health technology is a system focused through the Nx2me app that leverages tablets, cloud computing and wireless communications to collect home hemodialysis d...
Source: Mass Device - February 24, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Clinical Trials Dialysis NxStage Medical Inc. Source Type: news

Attenuation of Peritoneal Fibrosis by Interleukin-10Attenuation of Peritoneal Fibrosis by Interleukin-10
Might immunomodulation with interleukin-10 offer an effective therapeutic strategy for prevention or treatment of peritoneal fibrosis, a complication of peritoneal dialysis? Laboratory Investigation (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 18, 2016 Category: Pathology Tags: Nephrology Journal Article Source Type: news

NxStage slumps despite Q1, FY2015 beats
NxStage saw shares plummet after releasing earnings that barely squeaked by Street expectations for their 4th quarter and full fiscal year 2015. The Lawrence, Mass.-based company reported losses of $2.8 million, or 4¢ per share, on sales of $89.8 million for the 3 months ended December 31. That amounts to a 43.7% reduction in losses for the company as sales grew 12.4% compared with the same period in 2014. Analysts on Wall Street were looking for losses per share of 4¢, right on target with the reported losses, and revenues of $86.8 million, which the company beat. For the year, NxStage reported losses of $14.6 m...
Source: Mass Device - February 10, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup NxStage Medical Inc. Source Type: news

US FDA prioritizes devices requiring human factors reviews
By Stewart Eisenhart, Emergo Group US medical device regulators have specified types of devices for which premarket application submissions should include human factors testing information, according to new Food and Drug Administration guidance. The FDA guidance explains that devices it identifies warrant human factors data because of “clear potential for serious harm resulting from use error.” Such data is necessary for proper evaluation of safety, effectiveness and substantial equivalence, states the agency. Premarket applications for the following device types should include human factors testing reports un...
Source: Mass Device - February 8, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Emergo Group Source Type: news

What Factors Influence Linear Growth After Transplantation?
Discussion Growth is a defining characteristic of children. Children are expected to have normal height, weight and head circumference growth velocities for their specific age. A review of mid-parental height determination and other growth parameters can be found here. For children with chronic illness and organ dysfunction or failure, their bodies cannot be expected to continue to have normal growth and therefore these children often have failure of normal growth for any and all of the growth parameters. For children facing organ failure or high risk or relapsed cancers, organ transplantation can be life-saving, but is n...
Source: PediatricEducation.org - February 8, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Peritoneal Dialysis Solutions (Updated - Currently in Shortage)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 20, 2016 Category: Drugs & Pharmacology Source Type: news

Peritoneal Dialysis Solutions for Automated Peritoneal Dialysis (APD) therapy (Dianeal and Extraneal) (Updated - Currently in Shortage)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

Geriatric assessment, falls and rehabilitation in patients starting or established on peritoneal dialysis - Jassal SV.
Individuals aged over 70 years at the time of starting dialysis have a varied and often challenging existence on dialysis. Canadian data suggest those starting dialysis between the ages of 75 and 79 years will have an average life expectancy of 3.2 years, ... (Source: SafetyLit)
Source: SafetyLit - January 11, 2016 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

Rat Models of Acute and/or Chronic Peritoneal Injuries Including Peritoneal Fibrosis and Peritoneal Dialysis Complications
We describe herein two rat models of peritoneal injury that we have recently proposed. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - December 22, 2015 Category: Molecular Biology Source Type: news

Isolation and Propagation of Rat Peritoneal Mesothelial Cells
With the development of peritoneal dialysis in many countries, there has been much interest in the cell biology of peritoneal mesothelial cells. In this chapter we describe a reliable and reproducible method for the culture of rat primary mesothelial cells (RPMCs). This chapter outlines how to isolate mesothelial cells from rat peritoneum. The subculture of primary peritoneal mesothelial cells and the characterization by immunofluorescence is also described in detail. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - December 22, 2015 Category: Molecular Biology Source Type: news

Equivalent fall risk in elderly patients on hemodialysis and peritoneal dialysis - Farragher J, Rajan T, Chiu E, Ulutas O, Tomlinson G, Cook WL, Jassal SV.
Background: Accidental falls are common in the hemodialysis (HD) population. The high fall rate has been attributed to a combination of aging, kidney disease-related morbidity, and HD treatment-related hazards. We hypothesized that patients maintained on p... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - December 11, 2015 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

Debiotech, Fresenius partner to develop home dialysis tech
Swiss med device firm Debiotech and dialysis device developer Fresenius Medical said today they are partnering to develop home-usable peritoneal dialysis technologies. The companies said they aim to create a platform of dialysis machines that are lightweight and compact to allow patients to travel with the device and use them at home. The newly partnered companies added that they intended to develop an easy-to-pickup set of instructions for the devices to make them easier to adopt for new users. “This agreement represents an ideal synergy to help patients everywhere who suffer from end stage renal disease receiv...
Source: Mass Device - November 3, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Dialysis Research & Development Debiotech Fresenius Medical Care Source Type: news

NxStage Medical jumps on Q3 beat-and-raise, reveals pipeline
NxStage Medical (NSDQ:NXTM) shares started up today as investors reacted to beat-and-raise results for the home hemodialysis company’s 3rd-quarter and details about its development pipeline. Lawrence, Mass.-based NxStage said it narrowed its losses by -47.8% to -$1.7 million, or -3¢ per share, on sales growth of 14.9% to $86.5 million compared with Q3 2014. The consensus outlook on Wall Street was for losses of -8¢ on sales of $82.1 million. “Based on our performance and confidence around the 4th quarter, we are again raising our total revenue guidance for the year,” founder & CEO ...
Source: Mass Device - November 3, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Dialysis MassDevice Earnings Roundup Wall Street Beat NxStage Medical Inc. Source Type: news

Debiotech and Fresenius Medical Care Announce Exclusive Partnership for New Home Dialysis Product Development
LAUSANNE, Switzerland and BAD HOMBURG, Germany, November 3, 2015 -- (Healthcare Sales & Marketing Network) -- Debiotech SA, a Swiss medical device developer with expertise in innovative technologies and miniaturized medical equipment and devices, and Fres... DevicesDebiotech, Fresenius Medical Care, dialysis, peritoneal dialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 3, 2015 Category: Pharmaceuticals Source Type: news

FDA OKs Baxter's Automated Home Peritoneal Dialysis System FDA OKs Baxter's Automated Home Peritoneal Dialysis System
The AMIA system features two-way remote connectivity, touchscreen controls, and voice guidance for home delivery of peritoneal dialysis. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 16, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news